« Return to News | CROs/Service Providers

Charles River to Cut Headcount by 3% Due to Slow Q4

Wednesday, February 11, 2009 07:00 AM

Wilmington, Mass.-based Charles River Laboratories reported another quarter of slower than expected sales growth in its Preclinical Services Segment (PCS), prompting the company to announce cost-saving measures including a 3% reduction in headcount for the first quarter 2009.

Net sales for Q4 2008 decreased 2.1% to $311.4 million from $318 million in the fourth quarter of 2007. On a non-GAAP basis, net income was down 13.6% to $39.7 million for the fourth quarter of 2008, compared with $45.9 million for the same period in 2007. Fourth quarter diluted earnings per share on a non-GAAP basis were $0.59, a decrease of 9.2% compared with $0.65 per share in the fourth quarter of 2007.

“Our 2008 results reflect the impact of the global economic crisis and the challenges our pharmaceutical and biotechnology clients are facing, especially in the PCS segment,” said chairman, president and CEO James Foster in a company statement.

Net sales for the full year 2008 increased by 9.2% to $1.34 billion, from $1.23 billion in 2007. Net income for 2008 on a non-GAAP basis was $199.8 million, or $2.89 per diluted share, compared to $180.2 million, or $2.62 per diluted share, for 2007.

The also company released its guidance for 2009, predicting a 2% to 7% decrease in net sales due to a slow first quarter. The guidance assumes non-GAAP EPS for the first quarter of 2009 will be below the fourth quarter of 2008, but the company expects to see a stronger second half of the year. The non-GAAP EPS estimate for 2009 is $2.30 to $2.60.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.